Compare ADM & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADM | ONC |
|---|---|---|
| Founded | 1902 | 2010 |
| Country | United States | Switzerland |
| Employees | N/A | 12000 |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.6B | 40.6B |
| IPO Year | 2008 | 2015 |
| Metric | ADM | ONC |
|---|---|---|
| Price | $82.47 | $361.90 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 28 |
| Target Price | $80.40 | ★ $432.80 |
| AVG Volume (30 Days) | ★ 3.1M | 361.5K |
| Earning Date | 11-03-2026 | 11-10-2026 |
| Dividend Yield | ★ 2.58% | N/A |
| EPS Growth | N/A | ★ 140.43 |
| EPS | ★ 2.49 | 0.31 |
| Revenue | ★ $80,269,000,000.00 | $238,387,000.00 |
| Revenue This Year | $7.64 | $26.70 |
| Revenue Next Year | $4.82 | $14.57 |
| P/E Ratio | ★ $31.94 | $1,157.32 |
| Revenue Growth | N/A | ★ 22179.16 |
| 52 Week Low | $55.58 | $253.95 |
| 52 Week High | $88.75 | $385.22 |
| Indicator | ADM | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 50.08 | 53.46 |
| Support Level | $76.16 | $327.01 |
| Resistance Level | $84.10 | $370.11 |
| Average True Range (ATR) | 2.18 | 7.56 |
| MACD | -0.54 | -0.13 |
| Stochastic Oscillator | 42.67 | 61.40 |
Archer-Daniels-Midland is a major processor of oilseeds, corn, wheat, and other agricultural commodities. The company is also one of the largest grain merchandisers through its extensive network of logistical assets to store and transport crops around the globe. ADM also runs a nutrition business that focuses on both human and animal ingredients and is a large producer of corn-based sweeteners, starches, and ethanol.
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.